CaseVu
Precipio Announces Q2-2019 Corporate Update Call For Shareholders
Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW [...]
Aug
Global Expansion Efforts Begin Yielding Results
Asia is the first Key Geographic Focal Point NEW HAVEN, CT, (July 22nd, 2019) – Specialty [...]
Jul
Precipio And H3 Biomedicine Sign Second Development Agreement
Companies to create a panel amplifying targeted regions of key cancer genes NEW HAVEN, CT, [...]
Jun
Precipio CEO Provides Update Letter To Shareholders
NEW HAVEN, CT, (June 17th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to [...]
Jun
Precipio Signs Exclusive Manufacturing Agreement For IV-Cell™
NEW HAVEN, CT, (June 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has [...]
Jun
Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement In Q1-2019
Three key metrics are leading indicators of continuous revenue growth NEW HAVEN, CT, (May 30th, [...]
May
Precipio CEO Enrolls In Long Term Stock Purchase Plan
NEW HAVEN, CT, (May 23, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as [...]
May
Precipio Regains Nasdaq Listing Compliance
NEW HAVEN, CT, (May 15, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May [...]
May
Precipio Conducts IV-Cell™ Validation Trial With A Prominent Laboratory
NEW HAVEN, CT, (May 06, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is [...]
May
Precipio Successfully Completes Nasdaq Hearing Process
Company is expected to regain listing compliance upon completion of the remaining 10-day requirement NEW [...]
May